-
Phagocytic Giant Cancer Macrophages in Blood
2026-09-19
A 2025 Cancer Letters study reframes circulating phagocytic polyploid giant cancer macrophages, or CAMLs, as clinically informative and biologically active cells rather than cellular debris. In a prospective, multi-institutional cohort, CAMLs correlated with disease progression and displayed self-renewing, proangiogenic, and overlapping myeloid, epithelial, and endothelial features.
-
From Podocyte Pathways to Better Viability Data
2026-09-18
A translational perspective on how AO/PI Staining Solution can strengthen viability measurements in diabetic nephropathy research, using phillygenin pathway evidence to connect molecular mechanism with reproducible fluorescence-based cell counting.
-
Mithramycin A: A Mechanism-to-Assay Guide
2026-09-18
Mithramycin A is an anticancer antibiotic for dissecting G-C-rich transcriptional control, c-myc regulation, and differentiation. This guide connects its established cancer-biology uses with a rigorous assay framework inspired by the miR-24-3p/Sp1/PI3K study, while separating evidence from exploratory applications.
-
GSK 2837808A: A Flux-Resolved LDHA Strategy
2026-09-17
GSK 2837808A provides a selective way to interrogate LDHA-dependent lactate production without treating glycolysis as a single process. This article develops a flux-resolved framework for connecting glucose consumption reduction with the NAT1–ENO1–lactate–PD-L1 axis while separating validated findings from exploratory cancer metabolism research.
-
Lactate Workflows for Metabolic–Immune Research
2026-09-17
Use L-lactate as both a quantitative metabolic readout and a controlled signaling input across glycolysis, hypoxia, mitochondrial stress, and tumor–immune models. This workflow emphasizes compartment-specific sampling, fresh dosing, and mechanistic controls that distinguish lactate production from lactate-driven PD-L1 regulation.
-
MK-4827 (Niraparib) Lab Guide
2026-09-16
A scenario-based guide to using MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor, in cell viability, proliferation, and cytotoxicity workflows. It explains assay design, solvent handling, resistance models, data interpretation, and vendor-selection considerations for SKU A3617.
-
TH287 MTH1 Inhibitor for Radiosensitization
2026-09-16
TH287 turns MTH1 inhibition into a practical radiosensitization strategy for cancer-cell models, with the strongest reported effect when ionizing radiation follows drug exposure by 12 hours. This guide translates the finding into a controlled workflow, assay design, and troubleshooting plan for oxidative stress-induced DNA damage research.
-
10 mM dNTP Mixture: Reliable DNA Synthesis
2026-09-15
A scenario-based guide to using the 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture, SKU K1041, in PCR, qPCR, sequencing, and cell-assay workflows that depend on molecular readouts. It explains formulation, compatibility, storage, interpretation limits, and practical vendor-selection criteria without overstating what a nucleotide mix can do.
-
Z-WEHD-FMK for Caspase-1 Pyroptosis Studies
2026-09-15
Z-WEHD-FMK provides a cell-permeable, irreversible way to test inflammatory caspase involvement in pyroptosis, cancer biology, and infection models. This practical guide connects the HOXC8–caspase-1 findings in NSCLC with assay design, Chlamydia workflows, dosing, controls, and troubleshooting.
-
TMB in ELISA: From Redox Chemistry to Malaria
2026-09-14
TMB connects peroxidase chemistry with sensitive serological readouts. This guide explains how 3,3′,5,5′-Tetramethylbenzidine can support epitope-based Plasmodium vivax surveillance while preserving rigorous controls, cutoff validation, and assay interpretation.
-
NAT1–ENO1–Lactate Signaling in Colorectal Cancer
2026-09-14
A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that restrains ENO1 activity, lactate production, and TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated database, multi-omics, cellular, patient, and mouse-model evidence provides a mechanistic framework for linking tumor glycolysis with immune-checkpoint response, while also defining important limits for translating LDHA-focused experiments.
-
Bromodomain Inhibitor, (+)-JQ1: Ferroptosis Workflows
2026-09-13
Bromodomain Inhibitor, (+)-JQ1 provides a practical way to connect BET-dependent chromatin regulation with ferroptosis, apoptosis, inflammation, and BRDT biology. This guide converts the latest BRD4–ROS–FSP1 findings into a controlled cell-assay workflow with application-specific controls and troubleshooting strategies.
-
DAF-2 diacetate for Nitric Oxide Imaging
2026-09-12
DAF-2 diacetate combines cell permeability, intracellular retention, and sensitive fluorescence for mapping nitric oxide in live cells and experimental tissues. This practical guide connects probe handling with sulfur-dependent redox biology, including assay designs for endothelial, immune, neuronal, and soybean nodule research.
-
Bromodomain Inhibitor, (+)-JQ1 Workflow Guide
2026-09-11
Build reproducible BRD4 and BET-bromodomain experiments with (+)-JQ1, from dose-response and apoptosis assays to ferroptosis-combination studies. This workflow emphasizes solvent control, orthogonal readouts, and cell-context interpretation so researchers can distinguish transcriptional inhibition from downstream cell-death effects.
-
Lactate–GPR81–RAC1 Control of Glucose Uptake
2026-09-11
The 2026 Cell Research study identifies L-lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and connects this effect to a GPR81–FARP1–RAC1–GLUT4 signaling axis. Its genetic, metabolic, and human-association evidence suggests that exercise-associated lactate may complement insulin signaling, while also defining experimental opportunities and limits for testing RAC1-dependent glucose transport.